Regorafenib: carving a niche in the crowded therapeutic landscape

Author： Sirohi Bhawna   Philip Deepa Susan   Shrikhande Shailesh V  

Publisher： Informa Healthcare

ISSN： 1473-7140

Source： Expert Review of Anticancer Therapy, Vol.13, Iss.4, 2013-04, pp. : 385-393

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The changing landscape of therapeutic strategies for recurrent ovarian cancer

By Baumann Klaus H   Wagner Uwe   du Bois Andreas  

Future Oncology, Vol. 8, Iss. 9, 2012-09 ,pp. : 1135-1147

Future Medicine

Access to resources Recommend Favorite

Regorafenib use as a possible cause of intestinal perforation

By Adenis Antoine   Kotecki Nuria   Decanter Gauthier   Clisant Stéphanie   Penel Nicolas  

Acta Oncologica, Vol. 52, Iss. 8, 2013-11 ,pp. : 1789-1790

Informa Healthcare

Access to resources Recommend Favorite

Reversibility of regorafenib effects in hepatocellular carcinoma cells

By D’Alessandro Rosalba   Refolo Maria   Lippolis Catia   Messa Caterina   Cavallini Aldo   Rossi Roberta   Resta Leonardo   Carlo Antonio   Carr Brian  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 4, 2013-10 ,pp. : 869-877

Springer Publishing Company

Access to resources Recommend Favorite

How I Treat Metastatic Colorectal Cancer: Incorporating Regorafenib into Therapy

By Scheithauer Werner   Ychou Marc  

The Journal of OncoPathology, Vol. 2, Iss. 2, 2014-06 ,pp. : 11-18

Optimal Clinical Ltd

Access to resources Recommend Favorite

Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer

By Cremolini Chiara   Schirripa Marta   Loupakis Fotios   Falcone Alfredo  

Colorectal Cancer, Vol. 2, Iss. 5, 2013-10 ,pp. : 411-417

Future Medicine

Access to resources Recommend Favorite